2021

IDIBELL receives a grant from the Generalitat to promote Personalized Medicine on campus

The Generalitat of Catalonia has awarded IDIBELL a co-financed project of 2 million euros that will consolidate Personalized Medicine on the Bellvitge campus. The money will be used to create and improve infrastructures that allow the management and storage of patient samples and derived data, ensuring their integrity and traceability.

IDIBELL receives a grant from the Generalitat to promote Personalized Medicine on campus Read More »

Identified new susceptibility genes to inflammatory bowel diseases

A study led by IDIBELL and the ICO has analyzed genetic data from thousands of patients with inflammatory bowel disease through an innovative statistical approach that has made it possible to identify new susceptibility genes to this disease.

Identified new susceptibility genes to inflammatory bowel diseases Read More »

Light-activated drugs, localized medicine without side effects

A team from IDIBELL and the University of Barcelona has devised two treatments based on this innovative technology: a derivative of morphine that does not generate addition, a new treatment against psoriasis. Also they used this technology to determine the adenosine role in pain transmission.

Light-activated drugs, localized medicine without side effects Read More »

Scroll to Top